MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $131.01M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.57M
Average 0.98M
MGNX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
MacroGenics, Inc.NASDAQ: MGNX
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -161.0%
Operating margin was -161.0% in Q1 FY2026, up 162.1 pp from a year earlier. On a trailing-twelve-month basis it was -40.5%, up 24.7 pp year over year. Over 3 fiscal years it widened by 32.2 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of -106.4% for the fiscal year ending Dec 2026, down from -48.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -161.0%-131.6 pp QoQ
- Last fiscal yearDec 2025
- -48.7%+25.8 pp YoY
- LTMMar 2026
- -40.5%+24.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -48.7%
- Year-over-year change
- +25.8pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -48.7% | +25.8pp |
| FY2024 | 2024-12-31 | -74.5% | +219.6pp |
| FY2023 | 2023-12-31 | -294.2% | -213.2pp |
| FY2022 | 2022-12-31 | -80.9% | +187.2pp |
| FY2021 | 2021-12-31 | -268.1% | — |
Operating Margin vs competitors
How MGNX compares with its peers on the latest reported figures
- MGNX's LTM Mar 2026 operating margin of -40.5% is the highest of the 9 companies compared; the peer median is -3433.8%.
- Its year-over-year change of +24.7 pp is the 3rd highest of 8, against a peer median of -3640.0 pp.
- Over three fiscal years its change of +32.2 pp compares with a peer median of +747.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -277.0% | +250.6 pp | — | |
| LTM Mar 2026 | -670.2% | +9733.9 pp | +3111.2 pp | |
| FY2025 | -754.4% | — | +747.6 pp | |
WHWKWhitehawk Therapeutics Inc | FY2025 | -1601.1% | -1341.5 pp | -1189.2 pp |
| LTM Mar 2026 | -5266.4% | -3640.0 pp | +10697.2 pp | |
| LTM Mar 2026 | -15535.1% | -7553.1 pp | -1307.0 pp | |
| FY2025 | -90740.6% | -90654.4 pp | — | |
| LTM Mar 2026 | -144445.0% | -103193.3 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding MGNX) | -3433.8% | -3640.0 pp | +747.6 pp | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$2.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.